Mustang Bio, Inc. - MBIO STOCK NEWS

Mustang Bio, Inc. (NASDAQ: MBIO) announced its financial results for the year ending December 31, 2020, highlighting robust progress in its cell and gene therapy programs. Notable achievements include MB-106 showing an 89% overall response rate and 44% complete response rate in B-cell non-Hodgkin lymphoma trials. Financially, Mustang reported cash reserves of $98.8 million, up from $62.4 million in 2019. Despite increased R&D expenses totaling $37.2 million, the net loss rose to $60 million, or $1.14 per share. Looking ahead, Mustang plans to advance multiple clinical trials in 2021, targeting innovative therapies for rare diseases.

Mustang Bio, Inc. (NASDAQ: MBIO) announced its management team's participation in three virtual investor conferences in March 2021. The events include:

• H.C. Wainwright Global Life Sciences Virtual Conference on March 9, 2021, available on-demand.
• Oppenheimer 31st Annual Virtual Healthcare Conference on March 16, 2021, with a fireside chat at 3:10 p.m. ET.
• Redburn Virtual Gene Therapy Summit on March 31, 2021, at 9:15 a.m. ET.

Webcasts will be accessible on Mustang's website for 30 days following each event.

Mustang Bio (NASDAQ: MBIO) supports Rare Disease Day on February 28, aiming to enhance awareness of rare diseases. The company is committed to advancing treatments for conditions like X-linked severe combined immunodeficiency (XSCID) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). Two pivotal clinical trials for XSCID are set to begin this year, RESTORE and SUSTAIN, targeting young patients and those with prior stem cell transplants. Mustang's initiatives also include partnerships with patient advocacy groups. The company acknowledges the challenges faced by individuals with rare diseases as they work towards potential cures.

Mustang Bio, a clinical-stage biopharmaceutical company (NASDAQ: MBIO), announced its CEO, Manuel Litchman, will participate in three upcoming virtual investor conferences in January 2021. These include the 10th Annual LifeSci Partners Corporate Access Event from January 6-14, the H.C. Wainwright Virtual BioConnect Conference on January 11, and the B. Riley Securities’ Virtual Oncology Investor Conference on January 21. Presentations will be available on Mustang's website for 30 days following the events. Mustang focuses on cell and gene therapies for cancers and rare diseases.

Mustang Bio (NASDAQ: MBIO) has initiated a Phase 1 clinical trial at City of Hope to evaluate the safety and feasibility of MB-101 (IL13Rα2-CAR T cells) in treating patients with leptomeningeal brain tumors, including glioblastoma, ependymoma, and medulloblastoma. The trial will involve up to 30 patients and will assess toxicity and survival at three months, with additional secondary endpoints. The therapy previously showed promising results, including a complete response in a glioblastoma patient. The trial aims to provide a potential new treatment for these difficult-to-treat cancers.

Mustang Bio (NASDAQ: MBIO) presented promising interim data for MB-106, a CD20-targeted CAR T cell therapy, at the 62nd ASH Annual Meeting. The therapy showcased an impressive 89% overall response rate and a 44% complete response rate among nine patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Safety data indicated no neurotoxicity and low incidence of cytokine release syndrome. Mustang plans to file an Investigational New Drug application in Q1 2021 to start a Phase 2 trial, expanding eligibility to include chronic lymphocytic leukemia patients.

Mustang Bio (NASDAQ: MBIO) will host a key opinion leader call on December 9, 2020, at 1:00 p.m. EST to present interim Phase 1/2 data on MB-106, an innovative CAR T cell therapy targeting relapsed or refractory B-cell non-Hodgkin lymphoma. The call will feature Drs. Mazyar Shadman and Brian Till from Fred Hutchinson Cancer Research Center, discussing clinical findings and a modified cell manufacturing process. Additionally, Mustang will provide a corporate update and address audience questions following the presentations.

Mustang Bio (NASDAQ: MBIO) received a positive opinion from the European Commission for Orphan Drug Designation for its lentiviral gene therapy targeting X-linked severe combined immunodeficiency (XSCID). This designation applies to both MB-107 and MB-207 therapies. Key advantages include protocol assistance and 10 years of market exclusivity in the EU. Mustang is preparing for pivotal clinical trials for these treatments and expects to initiate them soon. Additionally, an agreement with Minaris Regenerative Medicine enables GMP manufacturing for clinical trials in Europe.

Mustang Bio (NASDAQ: MBIO) has partnered with Minaris Regenerative Medicine for the GMP clinical manufacturing of its MB-107 lentiviral gene therapy targeting X-linked severe combined immunodeficiency (XSCID) in Europe. The collaboration will facilitate technology transfer and support clinical trials for this rare genetic disorder, which affects 1 in 225,000 births. MB-107 is currently in Phase 1/2 trials in the U.S. with plans for a pivotal trial in Europe. Mustang aims to provide this therapy to patients internationally, targeting topline data by late 2022.